Share price
₹1,618 latest close · −3.1% over the last 90 sessions
₹1,618 month-end · +5.6% over 12 months
₹1,618 month-end · +2.3% since Jan '25
52-week range ₹1057.00 to ₹1917.80 · 1-year volatility 45.4%
How rough has the ride been?
Drawdown from peak
Largest drawdowns
-49.3% (2025-06 peak to 2026-01 low, not yet recovered)
-27.6% (2025-01 peak to 2025-02 low, recovered 2025-03)
-21.4% (2025-03 peak to 2025-04 low, recovered 2025-05)
Most recent volume spikes
2026-10-30: 5.9x the 50-day median, price -0.4% that day
2026-10-28: 24.3x the 50-day median, price -0.8% that day
2026-10-27: 50.9x the 50-day median, price +13.8% that day
Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- ROCE11th▼ 7 pts vs a year ago
- Op. margin83rdflat vs a year ago
- Revenue growth30th
- Debt/equity ↓53rd▼ 8 pts vs a year ago
- Cash cycle ↓15th▼ 22 pts vs a year ago
- P/E ↓2nd
- 12M momentum48th
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What is the price implying?
Trailing earnings per share are negative, so a P/E-based figure does not exist. See the loss-makers list on the Expectations Gap page for a revenue-based version.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What prices imply across Health Technology The market-wide Expectations lists
Key figures
- Share Priceclose 9 Nov
- ₹1618.00
- ROCE
- 1.0%
- Market Cap
- ₹18555 cr
- Revenue (TTM)
- ₹1543 cr
- P/S
- 12.0x
- P/B
- 3.2x
- ROE
- -0.8%
- Operating Margin
- 27.0%
- Debt / Equity
- 0.2x
- Promoter Holding
- 30.5%
- 12M Momentum
- 5.6%
52-week range
Price risk
Balance sheet & cash
Are profits backed by cash?
Other income reliance—Not enough data
Not enough reported data to compute this.
Tax rate—Not enough data
Not enough reported data to compute this.
Cash conversion—Not enough data
Not enough reported data to compute this.
Free cash flow0 of 5 yrsBeyond threshold
Fiscal years with positive free cash flow in the last 5: 0. Bands: at least 80% of years, 40% to 80%, below 40%.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress9% of fixed assetsWithin range
Capital work-in-progress is 9% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
Who has been buying and selling?
- Over 2 years, DIIs added 10.8 pts; promoters trimmed 7.3 pts; FIIs added 1.8 pts.
- The number of shareholders fell from 98,425 to 77,899 (-21%) between Dec 2024 and Jun 2026.
Holdings, Jun '26
How each group changed
Number of shareholders
Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.
What happened next to similar setups
- We found 50 past situations where a non-financial company looked like ONESOURCE SPECIALTY PHARMA LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
- Over the following 12 months the middle half of them returned −32% to +33% vs the market, against 0% for all non-financial companies in the same months.
- The analogs' median sat below that base rate (gap −9.9%, 80% range −20.4% to −4.6%), but the matches cluster in only 6 distinct 12-month windows.
Where the 50 outcomes landed
Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge
50 past situations · 50 companies · 36 months · 2020–2025
The closest matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| ORCHPHARMA Health Technology |
Mar 2023 | — | -2% | +34% | −11% | +84% |
| HEG Producer Manufacturing |
Aug 2021 | — | -2% | +163% | −7% | −48% |
| ASHIANA Finance |
Mar 2021 | — | -1% | +164% | −9% | −16% |
| BORORENEW Process Industries |
Sep 2025 | — | -4% | +17% | −12% | −21% |
| DELTACORP Consumer Services |
Jan 2022 | — | 0% | +88% | −9% | −29% |
Show the other 3 matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| DEN Consumer Services |
Apr 2020 | — | -1% | −16% | −42% | −49% |
| JAICORPLTD Process Industries |
Jan 2020 | — | 4% | +11% | −13% | −37% |
| GREAVESCOT Producer Manufacturing |
Mar 2022 | — | 3% | +50% | −24% | −31% |
How reliable is this?
Matched on P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, ROCE and drawdown from 12-month high. Not used (unavailable for this company): P/E. This company is loss-making, so it was only compared with loss-making companies. One match per company and at most 7 from any one month.
Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.
What else looks like this?
Companies with the most similar financial profile today, regardless of industry.
Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.
What changed?
24 events since Feb '25
- OctPriceVolume reached 50.9x its 50-day median on 2026-10-27; price +13.8% that day.
- SepResultsRevenue (TTM) reached a new high of ₹1,543 cr.
- SepInstitutionsFII + DII holding rose 4.5 pts over 2 quarters to 42.6%.
- SepPeer rankMoved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
- SepPriceVolume reached 14.4x its 50-day median on 2026-09-09; price -3.1% that day.
- JunResultsEPS (TTM) turned negative.
- JunPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the bottom quartile).
- AprPriceVolume reached 16.4x its 50-day median on 2026-04-21; price +0.7% that day.
Show 16 earlier events
- MarPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the top quartile).
- JanPriceFell 49% from the Jun 2025 peak to the Jan 2026 low.
- JanDebtDebt / equity halved over 12 months to 0.13x.
- JanSharesShare count is up 175.0% over 12 months.
- JanPriceVolume reached 23.8x its 50-day median on 2026-01-27; price -19.6% that day.
- DecResultsEPS (TTM) turned positive.
- DecPriceVolume reached 15.4x its 50-day median on 2025-12-19; price +5.0% that day.
- SepPromoterPromoter holding fell 4.5 pts to 29.8%.
- SepPriceVolume reached 5.2x its 50-day median on 2025-09-29; price +0.5% that day.
- JunPromoterPromoter holding fell 3.5 pts to 34.2%.
- JunInstitutionsFII + DII holding rose 6.6 pts over 1 quarter to 36.6%.
- JunDebtDebt / equity fell below 1.0x (0.13x).
- JunPriceVolume reached 12.2x its 50-day median on 2025-06-20; price -3.9% that day.
- MarPriceRegained the 2025-01 peak, 1 month after the low.
- MarPeer rankMoved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
- FebPriceFell 28% from the Jan 2025 peak to the Feb 2025 low.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history23 months · 2025-01 to 2026-11
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-11 | — | ₹1543 cr | -0.8% | 1.0% | 0.2x |
| 2026-10 | — | ₹1543 cr | -0.8% | 1.0% | 0.2x |
| 2026-09 | — | ₹1543 cr | -0.8% | 1.0% | 0.2x |
| 2026-08 | — | ₹1421 cr | -1.3% | 1.0% | 0.2x |
| 2026-07 | — | ₹1421 cr | -1.3% | 1.0% | 0.2x |
| 2026-06 | — | ₹1421 cr | -1.3% | 1.0% | 0.2x |
| 2026-05 | 1030.8x | ₹1419 cr | 0.3% | 6.0% | 0.1x |
| 2026-04 | 982.0x | ₹1419 cr | 0.3% | 6.0% | 0.1x |
| 2026-03 | 832.4x | ₹1419 cr | 0.3% | 6.0% | 0.1x |
| 2026-02 | 385.9x | ₹1522 cr | 0.7% | 6.0% | 0.1x |
| 2026-01 | 342.3x | ₹1522 cr | 0.7% | 6.0% | 0.1x |
| 2025-12 | 518.8x | ₹1522 cr | 0.7% | 6.0% | 0.1x |
| 2025-11 | — | ₹1480 cr | -0.2% | 6.0% | 0.1x |
| 2025-10 | — | ₹1480 cr | -0.2% | 6.0% | 0.1x |
| 2025-09 | — | ₹1480 cr | -0.2% | 6.0% | 0.1x |
| 2025-08 | — | ₹1445 cr | -0.3% | 6.0% | 0.1x |
| 2025-07 | — | ₹1445 cr | -0.3% | 6.0% | 0.1x |
| 2025-06 | — | ₹1445 cr | -0.3% | 6.0% | 0.1x |
| 2025-05 | — | ₹1092 cr | -39.6% | -12.0% | 1.4x |
| 2025-04 | — | ₹1092 cr | -39.6% | -12.0% | 1.4x |
| 2025-03 | — | ₹1092 cr | -39.6% | -12.0% | 1.4x |
| 2025-02 | — | ₹755 cr | -55.1% | -12.0% | 1.4x |
| 2025-01 | — | ₹755 cr | -55.1% | -12.0% | 1.4x |